Tuesday, September 29, 2015
Cloud Pharmaceuticals, a cloud-based drug design and development company located in Research Triangle Park, N.C., and Switzerland-based THERAMetrics have formed a strategic collaboration focusing on the design and development of therapeutics for orphan central nervous system (CNS) diseases and other indications.
New York-based ProPhase, a global provider of measurement expertise in clinical trials, and Malvern, Pa.-based YPrime, a clinical trial software products and services company, have formed a strategic partnership to develop digital products that create new clinical trial standardization processes and tools, from trial design and patient selection to using data analytics to improve endpoints and study results.
A new website for SBP Digital Trust Consulting has launched as a resource for biopharmaceutical managers seeking guidance for a range of IT issues, including establishing secure global collaborations, improving workflows and meeting international regulatory IT requirements. The site lists a selection of prominent security, identity and access management (IAM) and technology consultants serving the biopharmaceutical and related industries.
ERT, a Philadelphia-based global provider of patient safety and efficacy endpoint data collection, cloud analytics and workflow solutions, has expanded its line of centralized respiratory solutions for global clinical trials. The offering enables trial sponsors to improve investigative site performance, trial efficiencies and data quality by leveraging centralized data surveillance to support risk-based monitoring in respiratory clinical research.
The number of mobile health applications available to consumers now surpasses 165,000, as developers incorporate innovative data collection features linked to sensors and wearables, according to a new report released by the IMS Institute for Healthcare Informatics. While most available apps focus on overall wellness, healthcare systems and professionals are expressing greater interest and excitement in broader app use as barriers to mainstream adoption of mHealth are removed—especially in the area of chronic disease management.
The Undiagnosed Diseases Network (UDN), a clinical research initiative of the National Institutes of Health, has opened an online patient application portal called the UDN Gateway. Introduction of this application system sets the stage for the network to advance its core mission: to diagnose patients who suffer from conditions that even skilled physicians have been unable to diagnose despite extensive clinical investigation. These diseases are difficult for doctors to diagnose because they are rarely seen, have not previously been described or are unrecognized forms of more common diseases.
Optimal Strategix Group (OSG), based in Newtown, Pa., has launched its CAVII app, available for download in the Apple App Store. CAVII is an iOS-based clinical study matching and analytics platform. Ushering in a new era of patient engagement, CAVII’s aim is to revolutionize clinical studies through the use of analytics for superior patient matching. Through CAVII, clinical studies could become more cost-effective, efficient and ultimately more engaging and insightful for patients and clinicians.
PeptiDream, a public Tokyo-based biopharmaceutical company, has announced a multi-target discovery and optimization collaboration with Sanofi. PeptiDream will use its proprietary Peptide Discovery Platform System (PDPS) technology to generate macrocyclic/constrained peptides against multiple targets of interest selected by Sanofi. Sanofi will have the right to develop and commercialize all therapeutic peptides resulting from the collaboration.